Background It has been reported that people with COVID‐19 and pre‐existing
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm …

Background Randomized controlled trials (RCT) established the mortality reduction by
tocilizumab (Actemra), baricitinib (Olumiant), and sarilumab (Kevzara) in hospitalized COVID …

Despite global vaccination programs, infections with severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) continue to cause severe disease with significant morbidity …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has been a serious threat to
global health for nearly 3 years. In addition to pulmonary complications, liver injury is not …

This study investigated the efficacy and safety of interleukin-6 (IL-6) receptor antagonists
with standard care treatment in patients with coronavirus disease 2019 (COVID-19). The …

Aim Many randomized controlled trials (RCTs) have investigated the use of interleukin 6
antagonists for the treatment of coronavirus disease 2019 (COVID‐19), yielding inconsistent …

Abstract Introduction The Australian National COVID‐19 Clinical Evidence Taskforce was
established in March 2020 to maintain up‐to‐date recommendations for the treatment of …

Cancer patients, due to their immunocompromised status, are at an increased risk for severe
SARS-CoV-2 infection. Since severe SARS-CoV-2 infection causes multiple organ damage …

The COVID-19 pandemic, caused by the rapidly spreading SARS-CoV-2 virus, led to the
unprecedented mobilization of scientists, resulting in the rapid development of vaccines and …

The study aimed to evaluate severe COVID-19 treatment approaches. We conducted a meta-
analysis of randomized controlled trials (RTCs) with standard of care (SoC) as a control …